Meeting
2017 ASCO Annual Meeting
Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.
Authors
Ellen K. Ritchie
Weill Cornell Medical College, New York, NY
Ellen K. Ritchie , Johannes E. Wolff , Dominick Latremouille-Viau , Annie Guerin , Irina Pivneva , Owanate Briggs , George J. Joseph , Ehab L. Atallah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7052)
DOI
10.1200/JCO.2017.35.15_suppl.7052
Abstract #
7052
Poster Bd #
252
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.
First Author: Ehab L. Atallah
Poster
2013 ASCO Annual Meeting
Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network.
First Author: Kathryn S. Kolibaba
Poster
2013 ASCO Annual Meeting
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
First Author: Lei Chen
First Author: Ronald J. Rieder